Abstract
A multicenter double blind comparison was performed to evaluate the usefulness of Nsp for patients with nasal allergy. A total of 154 patients were studied. Nsp or placebo was intramuscularly injected 10 times at intervals of every other or every third day in dose of 3ml.
The results are as follows:
Nsp was significantly superior to placebo with regard to final global improvement rating and global utility rating with no relation to factors such as sex, age, type, severity and duration of the disease.
Side effects induced were minimum without any significant difference between the two groups.